TY - JOUR
T1 - When does Parkinson disease start?
AU - Savica, Rodolfo
AU - Rocca, Walter A.
AU - Ahlskog, J. Eric
PY - 2010/7
Y1 - 2010/7
N2 - There is convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathological findings or striatal dopamine imaging suggested a 5- to 6-year preclinical period. However, more recent evidence of Lewy body pathology in other neuronal populations preceding nigral involvement suggests that the preclinical phase may be much longer. Epidemiologic studies of nonmotor manifestations, such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder (RBD), and anemia, suggest that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.
AB - There is convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathological findings or striatal dopamine imaging suggested a 5- to 6-year preclinical period. However, more recent evidence of Lewy body pathology in other neuronal populations preceding nigral involvement suggests that the preclinical phase may be much longer. Epidemiologic studies of nonmotor manifestations, such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder (RBD), and anemia, suggest that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.
UR - http://www.scopus.com/inward/record.url?scp=77955016727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955016727&partnerID=8YFLogxK
U2 - 10.1001/archneurol.2010.135
DO - 10.1001/archneurol.2010.135
M3 - Review article
C2 - 20625084
AN - SCOPUS:77955016727
SN - 0003-9942
VL - 67
SP - 798
EP - 801
JO - Archives of Neurology
JF - Archives of Neurology
IS - 7
ER -